science
Definium Shares Rise 55% After LSD-Based Drug Meets Main Goal in Depression Trial
Definium Therapeutics reported that a single dose of its experimental drug DT120 reduced major depression symptoms in a late-stage trial. Shares jumped 55% to a more than four-year high.
New York PostAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Definium Therapeutics said a single dose of its experimental drug DT120 reduced symptoms of major depression in a late-stage trial, New York Post reported. Patients recorded scores on a standard depression scale that were 8.1 points lower than those on placebo after six weeks, meeting the trial’s main goal.
The pill is a pharmaceutical formulation of lysergide, also known as LSD, and belongs to the class of classic psychedelics that activate serotonin receptors in the brain.
The trial enrolled 149 participants aged 18-74 years with major depressive disorder. Definium shares rose 55% on Monday to a more than four-year high, New York Post reported. The stock has gained about 174% so far this year and was trading up 52% at $37.23.
She added that DT120 showed greater reductions in depression scores at six weeks than Johnson & Johnson’s Spravato and Compass Pathways’ COMP360 achieved at week four. The drug was generally well-tolerated, with 99% of adverse events mild to moderate and occurring mainly on the day of dosing, New York Post reported. No serious safety issues or increase in suicidal thoughts were observed.
In April, President Trump signed an executive order to speed up access to psychedelic-based treatments. Definium said the data brings it closer to a Food and Drug Administration submission, and it was running a second late-stage depression trial.
